Monoclonal antibodies and prostate-specific membrane antigen

Current Opinion in Investigational Drugs

Volumn 5, Issue 6, 2004, Pages 611-615

  Chang, Sam S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Angiogenesis; Monoclonal antibody; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

BIOLOGICAL MARKER; DIAGNOSTIC AGENT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

BIOSYNTHESIS; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PROSTATE TUMOR; RADIOGRAPHY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 4043059477     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res (1987) 7(5B):927-936.
2. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res (1990) 50(19):6423-6429.
3. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 54(24):6306-6310.
4. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 3(1):81-85.
5. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer (1995) 62(5):552-558.
6. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM et al: Prostate-specific membrane antigen: Evidence for the existence of a second related human gene. Br J Cancer (1995) 72(3):583-588.
7. Denekamp J, Dasu A, Waites A: Vasculature and microenvironmental gradients: The missing links in novel approaches to cancer therapy? Adv Enzyme Regul (1998) 38:281-299.
8. Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 53(2):227-230.
9. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WDW: Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 2(9):1445-1451.
10. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA (1996) 93(2):749-753.
11. Halsted CH, Ling EH, Luthi-Carter R, Villanueva JA, Gardner JM, Coyle JT: Folylpoly-γ-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem (1998) 273(32):20417-20424.
12. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate Specific membrane antigen. J Urol (2003) 170(5):1717-1721.
13. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH: Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol (2003) 170(6 Pt 2):S84-88.
14. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate (1997) 30(4):232-242.
15. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 57(17):3629-3634.
16. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB: Identification of a novel tumor-associated neovasculature. Clin Cancer Res (1999) 5(10):2674-2681.
17. Barren RJ 3rd, Holmes EH, Boynton AL, Gregorakis A, Elgamal AA, Cobb OE, Wilson CL, Ragde H, Murphy GP: Method for identifying prostate cells in semen using flow cytometry. Prostate (1998) 36(3):181-188.
18. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 58(18):4055-4060.
19. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res (2000) 60(18):5237-5243.
20. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res (1998) 58(21):4787-4789.
21. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL: Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer (2001) 92(6):871-876.
22. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 44(4):610-617.
23. Doehn C, Jocham D: Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium. Curr Opin Mol Ther (2002) 4(6):606-613.
24. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res (1997) 57(12):2321-2324.
25. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer (1998) 82(11):2256-2261.
26. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 48(2):326-334.
27. Chang SS, Bander NH, Heston WDW: Monoclonal antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer - focus on prostate-specific membrane antigen? Curr Opin Urol (2000) 9(5):391-395.
28. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT: Dissociation between androgen responsiveness for malignant growth vs expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 54(4):249-257.
29. Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL Jr: Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res (1999) 5(12):4034-4040.
30. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res (1992) 52(21):6110-6112.
31. Llanes L, Ferruelo A, Paez A, Gomez JM, Moreno A, Berenguer A: The clinical utility of the prostate specific membrane antigen reverse- transcription/polymerase chain reaction to detect circulating prostate cells: An analysis in healthy men and women. BJU Int (2002) 89(9):882-885.
32. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage. Cancer Res (1998) 58(7):1456-1459.
33. Petronis JD, Regan F, Lin K: Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med (1998) 23(10):672-677.
34. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, Maguire R, Rogers B, Olsen JO, Badalament RA: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 83(4):739-747.
35. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol (1994) 152(5 Pt 1):1490-1495.
36. 111indium-capromab pendetide immunoscintigraphy in the prediction lymph node involvement in high-risk prostate carcinoma patients. Cancer (1999) 85(7):1586-1592.
37. Raj GV, Partin AW, Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer (2002) 94(4):987-996.
38. Ellis RJ, Kim EY, Conant R, Sodee DB, Spirnak JP, Dinchman KH, Beddar S, Wessels B, Resnick MI, Kinsella TJ: Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys (2001) 49(5):1281-1286.
39. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol (1999) 161(2):597-598.
40. Gong MC, Chang SS, Sadelain M, Bander NH, Heston WDW: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev (1999) 18(4):483-490.
41. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M: Human Tlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRξ /CD28 receptor. Nat Biotechnol (2002) 20(1):70-75.
42. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP: Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate (1998) 35(2):144-151.
43. Weijerman PC, Zhang Y, Shen J, Dubbink HJ, Romijn JC, Peehl DM, Schroder FH: Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines. Urology (1998) 51(4):657- 662.
44. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G: The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer (1986) 38(1):47-53.
45. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol (1998) 16(8):2659-2671.
46. Noss KR, Wolfe SA, Grimes SR: Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene (2002) 285(1-2):247-256.